Vascular endothelial growth factor (VEGF) has an ability to induce functional osteoclasts as well as neovascularization. We recently reported that the number of osteoclasts was enhanced by the injection of recombinant human VEGF (rhVEGF) with the application of mechanical force for experimental tooth movement. In this study, the expression of VEGF was detected in osteoblasts on the tension side of the alveolar bone. Moreover, the rate of tooth movement was significantly increased in the rhVEGF injection groups compared with the controls. These results suggested that VEGF, highly expressed by mechanical stimuli, enhances the number of osteoclasts as a paracrine factor, and that the amount of tooth movement is accelerated by both endogenous VEGF and injected rhVEGF.
Get full access to this article
View all access options for this article.
References
1.
Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D -1996-. Migration of human monocytes in response to vascular endothelial growth factor -VEGF- is mediated via the VEGF receptor flt-1. Blood87:3336–3343.
2.
Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR -1992-. Vascular permeability factor -vascular endothelial growth factor- gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell3:211–220.
3.
Clauss M, Weich H, Breier G, Knies U, Röckl W, Waltenberger J, et al. -1996-. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem271:17629–17634.
4.
Collins MK, Sinclair PM -1988-. The local use of vitamin D to increase the rate of orthodontic tooth movement. Am J Orthod Dentofacial Orthop94:278–284.
5.
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT -1992-. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science255:989–991.
6.
Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML -1995-. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn203:80–92.
7.
Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR -1995-. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol107:233–235.
8.
Felix R, Cecchini MG, Fleisch H -1990-. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology127:2592–2594.
9.
Ferrara N, Houck K, Jakeman L, Leung DW -1992-. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev13:18–32.
10.
Harada S, Nagy JA, Sullivan KA, Thomas KA, Endo N, Rodan GA, et al. -1994-. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest93:2490–2496.
11.
Hofstetter W, Wetterwald A, Cecchini MC, Felix R, Fleisch H, Mueller C -1992-. Detection of transcripts for the receptor for macrophage colony-stimulating factor, c-fms, in murine osteoclasts. Proc Natl Acad Sci USA89:9637–9641.
12.
Kaku M, Niida S, Kawata T, Maeda N, Tanne K -2000-. Dose- and time-dependent changes in osteoclast induction after a single injection of vascular endothelial growth factor in osteopetrotic mice. Biomed Res21:67–72.
13.
Kaku M, Kohno S, Kawata T, Fujita I, Tokimasa C, Tsutsui K, et al. -2001-. Effects of vascular endothelial growth factor on osteoclast induction during tooth movement in mice. J Dent Res80:1880–1883.
14.
Kodama H, Yamasaki A, Nose M, Niida S, Ohgame Y, Abe M, et al. -1991a-. Congenital osteoclast deficiency in osteopetrotic -op/op- mice is cured by injections of macrophage colony-stimulating factor. J Exp Med173:269–272.
15.
Kodama H, Nose M, Niida S, Yamasaki A -1991b-. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med173:1291–1294.
16.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. -1998-. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell93:165–176.
17.
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N -1989-. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science246:1306–1309.
18.
Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Moller NP, Risau W, et al. -1993-. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell72:835–846.
19.
Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, et al. -1999-. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med190:293–298.
20.
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF -1983-. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science219:983–985.
21.
Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, et al. -1990-. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene -flt- closely related to the fms family. Oncogene5:519–524.
22.
Stark TM, Sinclair PM -1987-. Effects of pulsed electromagnetic fields on orthodontic tooth movement. Am J Orthod Dentofac Orthop91:91–104.
23.
Takano-Yamamoto T, Kawakami M, Kobayashi Y, Yamashiro T, Sakuda M -1992-. The effect of local application of 1,25-dihydroxycholecalciferol on osteoclast numbers in orthodontically treated rats. J Dent Res71:53–59.
24.
Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, et al. -1992-. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun187:1579–1586.
25.
Wiktor-Jedrzejczak W, Urbanowska E, Aukerman SL, Pollard JW, Stanley ER, Ralph P, et al. -1991-. Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. Exp Hematol19:1049–1054.
26.
Yamasaki K, Shibata Y, Imai S, Tani Y, Shibasaki Y, Fukuhara T -1984-. Clinical application of prostaglandin E1 -PGE1- upon orthodontic tooth movement. Am J Orthod85:508–518.
27.
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. -1998-. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA95:3597–3602.
